Christian-H. Heeger: Does the CHAMPION AF Trial Signal a Potential Paradigm Shift in Stroke Prevention for AF?
Christian-H. Heeger, Head of the Department of Rhythmology at Asklepios Hamburg Altona, Professor of Electrophysiology at University of Lübeck, shared on LinkedIn:
”New evidence in stroke prevention for atrial fibrillation – a potential paradigm shift?
The CHAMPION AF trial is the first large randomized study evaluating the WATCHMAN FLX™ system as a first-line therapy compared to direct oral anticoagulants (DOACs).
Why does this matter?
DOACs remain the standard of care for stroke prevention in non-valvular atrial fibrillation.
However, long-term bleeding risk continues to be a major clinical concern.
Study overview (CHAMPION-AF):
- Randomized controlled trial with ~3,000 patients worldwide
- Comparison: Left atrial appendage closure (LAAC) vs. DOAC therapy
- Multi-year follow-up
Primary endpoints:
- Stroke, cardiovascular death, and systemic embolism (non-inferiority)
- Non-procedural bleeding (superiority)
Study objective:
To demonstrate that a one-time interventional approach can provide a safe and effective long-term alternative to chronic anticoagulation – even in patients without contraindications to oral anticoagulants.
What could this mean for clinical practice?
If confirmed, these findings could significantly expand the role of LAAC—potentially positioning it as an earlier treatment option in stroke prevention strategies for atrial fibrillation.
A highly anticipated study with the potential to reshape treatment pathways.
With Option and Champion patients after or during PVI will also benefit from this strategy!”
Stay updated with Hemostasis Today.
-
Nov 19, 2026, 15:58Hema Goyal: Hematocon 2026 Bringing Together Knowledge, Innovation and Excellence in Hematology
-
Nov 19, 2026, 15:44Chukwuemeka Amarachi: Understanding Complex Blood Grouping Beyond Routine ABO And RhD Typing
-
Nov 19, 2026, 14:19Long-Read Sequencing Is Closing Diagnostic Gaps in Inherited Bleeding Disorders
-
Nov 19, 2026, 13:36Raja Prince: Protein S Silencing and the Future of Hemostatic Therapy
-
Nov 19, 2026, 13:26M. Sekip Altunkan: The Thrombotic Risk of Andexanet Alfa
-
Nov 19, 2026, 13:18Felice Gragnano: Personalizing Antiplatelet Therapy After PCI
-
Nov 19, 2026, 13:11When Postpartum Warning Signs Are Ignored – National Blood Clot Alliance
-
Nov 19, 2026, 12:56Batool Abuhalimeh: The Hidden Psychological Burden of Pulmonary Embolism
-
Nov 19, 2026, 12:45Pedro Perez: PE Recovery – From Acute Treatment to Long-Term Follow-Up